CardioSCORE: Pivotal trial data

Data from the U.S. pivotal BioImage Study in 6,600 subjects with no prior history of cardiovascular disease showed that testing with BG Medicine's CardioSCORE diagnostic at baseline significantly improved the identification of subjects at high risk for near-term major cardiovascular events over conventional risk scoring throughout a median follow-up of 2.5 years. Specifically, the addition of CardioSCORE testing to the Framingham Risk Score assessment had 60% sensitivity for identifying all subjects who experienced a major cardiovascular event within 1 year as high risk compared to 28% using only the Framingham Risk Score (p<0.0001). Within 2 years, CardioSCORE plus Framingham Risk Score had 54% sensitivity for identifying all subjects who experienced a major cardiovascular event as high risk compared to 26% using Framingham Risk Score alone (p<0.0001). In the study, 292 subjects experienced a qualifying major cardiovascular event or death. ...